Brave Asset Management Inc. lessened its holdings in Gilead Sciences (NASDAQ:GILD) by 30.4% during the 4th quarter, Holdings Channel reports. The firm owned 17,594 shares of the biopharmaceutical company’s stock after selling 7,682 shares during the period. Brave Asset Management Inc.’s holdings in Gilead Sciences were worth $1,260,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Welch Investments LLC bought a new position in Gilead Sciences during the 3rd quarter worth approximately $108,000. Wealthcare Advisory Partners LLC bought a new position in Gilead Sciences during the 3rd quarter worth approximately $133,000. Horan Capital Advisors LLC. bought a new position in Gilead Sciences during the 3rd quarter worth approximately $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Gilead Sciences during the 2nd quarter worth approximately $147,000. Finally, Hanson & Doremus Investment Management boosted its stake in Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the last quarter. 77.91% of the stock is currently owned by institutional investors.
NASDAQ GILD opened at $75.39 on Monday. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.67 and a current ratio of 2.74. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $89.54. The company has a market capitalization of $98,297.25, a PE ratio of 8.81, a price-to-earnings-growth ratio of -1.73 and a beta of 1.24.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were issued a $0.57 dividend. The ex-dividend date of this dividend was Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.02%. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.
In other news, CFO Robin L. Washington sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total value of $401,550.00. Following the sale, the chief financial officer now directly owns 23,749 shares in the company, valued at $1,907,282.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP James R. Meyers sold 100,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the completion of the sale, the executive vice president now owns 102,715 shares in the company, valued at $8,241,851.60. The disclosure for this sale can be found here. Insiders sold 441,934 shares of company stock worth $34,979,151 over the last quarter. 1.30% of the stock is owned by corporate insiders.
GILD has been the topic of several recent analyst reports. Maxim Group set a $94.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Monday, December 11th. Credit Suisse Group reissued a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research note on Thursday, December 7th. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price objective on the stock. in a research note on Wednesday, January 17th. Jefferies Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $81.19 to $93.00 in a research note on Friday, January 26th. Finally, Citigroup raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating and reduced their price objective for the stock from $88.80 to $76.00 in a research note on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $88.61.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.wkrb13.com/2018/04/02/brave-asset-management-inc-sells-7682-shares-of-gilead-sciences-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.